KYOWA-KIRIN
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) and a Japan-based global specialty pharmaceutical company, announced today the signing of a Promotion and Distribution Agreement with NewBridge Pharmaceuticals for the distribution of its existing rare disease portfolio across the Middle East and North Africa (MENA).
Under the terms of the agreement, NewBridge will commercialise CRYSVITA® (burosumab) for the treatment of X-Linked Hypophosphataemia (XLH) and Tumour-Induced Osteomalacia (TIO), as well as POTELIGEO® (mogamulizumab) for two subtypes of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin’s lymphoma.
As part of the agreement, NewBridge will exclusively distribute the two products across MENA countries of Algeria, Iraq, Libya and Jordan. KKI and NewBridge also hope to collaboratively address a number of challenges facing the rare disease community in the region by supporting disease awareness, improving time to diagnosis, and improving access to innovative treatments indicated for rare and orphan diseases.
Jeremy Morgan, President of KKI, commented: “At Kyowa Kirin our purpose is to deliver life-changing medicines and make people smile. We are pleased to be entering into this agreement with NewBridge Pharmaceuticals who have a clear mission to transform the lives of MENA patients and their families. With a commitment to delivering life changing value for people impacted by under-diagnosed and under-served diseases, this agreement is key to ensuring patients living with XLH, TIO and CTCL are able to access the medicines they need, and is another positive step on our journey.”
"Given the high prevalence of rare diseases in the MENA region, I am personally inspired and proud that we at NewBridge are building on our existing partnership with Kyowa Kirin with the addition of their rare disease products to our region,” added Joe Henein, President & CEO of NewBridge Pharmaceuticals. “This collaboration totally aligns with our mission to provide access to new therapies for patients, aiming to alleviate their suffering and enhancing their quality of life."
About CRYSVITA (burosumab)
CRYSVITA (burosumab) is a recombinant human monoclonal antibody (mAb) that binds to the protein fibroblast growth factor 23 (FGF23). This has the impact of inhibiting the action of FGF23, allowing phosphate regulation in the body to be restored.1
About POTELIGEO (mogamulizumab)
Mogamulizumab is a first-in-class humanised mAb directed against CC chemokine receptor 4 (CCR4), a protein consistently expressed in both mycosis fungoides and Sézary syndrome2–4 once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.5
About Kyowa Kirin
Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions—Japan, Asia Pacific, North America, and EMEA/International.
You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialise innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.
For more information, please visit www.nbpharma.com
References
1Electronic Medicines Compendium. Crysvita 10 mg solution for injection. Available from: https://www.medicines.org.uk/emc/product/9779/smpc#gref. Last accessed: November 2023.
2Ferenczi K, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405–10.
3Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood. 2002;99(5):1505–11.
4Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res. 2003;9:3625–34.
5Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–174.
KKI/INT/KKI/0959
Date of preparation: July 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807411936/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and fixed-wing market debut14.10.2025 20:39:00 CEST | Press release
During the National Business Aviation Association – Business Aviation Convention & Exhibition (NBAA-BACE), TRU Simulation + Training Inc., a Textron Inc.(NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced an agreement with the US Aviation Academy for its purchase of five of TRU Simulation’s Cessna Skyhawk Veris Virtual Reality (VR) Simulators. This landmark agreement introduces the Veris to the fixed-wing training market and is TRU Simulation’s first fleet order for VR training devices. The US Aviation Academy has the option for a future purchase of ten additional units as part of the agreement, underscoring a shared commitment to advancing pilot training through cutting-edge VR simulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013144401/en/ TRU Simulation and US Aviation Academy sign purchase agreement for five Cessna Skyhawk Veris Virtual Reality Simulators, signifying first fleet order and
Introducing Lasso: A New Food Tech Company Redefining Consumer Packaged Foods14.10.2025 19:34:00 CEST | Press release
Backed by $6.5M in new funding, Lasso is filling a void in the food industry with its proprietary fiber spinning technology that transforms simple ingredients into clean-label, protein-packed foods. Lasso today announced its official launch and the introduction of its proprietary technology, Lasso SpinTech. This breakthrough system upends the outdated standards of ultra-processed foods using physics to weave together protein and fiber to make previously unattainable new consumer products. With a new $6.5M raise, Lasso is bringing its technology to the world by launching its own brands and licensing to global partners to create a new generation of healthier foods. Guided by CEO Mike Messersmith, the Lasso team spent the past year deploying its commercial-scale technology to create innovative clean-label products including protein-packed snacks and pet food—expanding beyond its first plant-based meat application under the Tender Food brand. Lasso’s latest $6.5M in capital, led by Rhapsod
Rimini Street to Report Third Quarter 2025 Financial Results on October 30, 202514.10.2025 18:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on October 30, 2025. The company will host a conference call and webcast on that date to discuss the third quarter and the 2025 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014139026/en/ A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven,
Esri’s ArcGIS Maritime to Support Next-Generation S-100 Production Capabilities for Advanced Nautical Charting14.10.2025 18:00:00 CEST | Press release
Hydrographic Offices Can Seamlessly Transition to New Standards While Still Maintaining S-57 Charts Esri, the global leader in geographic information system (GIS) technology, announced new capabilities in ArcGIS Maritime to support production of S-100 compliant nautical charts, marking a major milestone in the evolution of hydrographic data management. Maritime organizations will also be able to generate S-57 charts alongside S-101 charts, which will enable them to more seamlessly leverage GIS. Crucial for supporting the latest spatial data and technologies, the shift to S-100 ready charting will enhance maritime navigation, safety, and situational awareness. The new S-100 series of standards developed by the International Hydrographic Organization (IHO) introduces a modern, extensible framework for electronic navigational charts, bathymetric data, and other marine information products. “The core mission of maritime authorities like hydrographic offices is supporting safe navigation, b
Best-Selling Cessna Citation Latitude Reach Continues to Grow With First Order in Argentina14.10.2025 17:59:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company has announced the first order of its best-selling Cessna Citation Latitude in Argentina. The aircraft, which continues to grow in popularity, was ordered by longtime Citation customer, Jet Clipper S.A., a charter operator in Argentina also covering Uruguay and Paraguay; it is expected to be delivered in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014636481/en/ Best-selling Cessna Citation Latitude reach continues to grow with first order in Argentina (Photo Credit: Textron Aviation). “In a region where time and access are critical, the Citation Latitude’s range and short-field capabilities empower customers to reach remote destinations quickly and efficiently,” said Marcelo Moreira, vice president, Sales, Latin America. “The Latitude will support the customer's existing operations by offering the perfect balance of performance and comfort expected from a C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom